STAT+: Unpacking Trump\u2019s approach to health care oversight
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
You\u2019re reading the web edition of D.C. Diagnosis, STAT\u2019s twice-weekly newsletter about the politics and policy of health and medicine.\u00a0Sign up here<\/a>\u00a0to receive it in your inbox on Tuesdays and Thursdays.<\/em><\/p>\n I was reminded recently of why I dig mass transit upon overhearing the train conductor and two middle-aged men engaged in a serious talk about mattresses, \u201ctrash\u201d 400-thread-counts, and the pros and cons of weighted sheets. Send me your suggestions for a luxurious night\u2019s sleep, and news tips to John.Wilkerson@statnews.com<\/a> or John_Wilkerson.07 on Signal.<\/p>\n Sarepta Therapeutics, which has come under regulatory pressure over its gene therapy for Duchenne muscular dystrophy, hired the Trump-connected lobbying firm<\/a> Michael Best Strategies after the death of a teenage boy<\/a> treated with the drug, according to lobbying disclosure reports.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\nIt\u2019s who you know that matters<\/h2>\n